Physician profile
Frederick D Heard
NPI 1972536068
$603.67
in general payments reported to CMS, 2019-2025
10 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2022: $83.88 · 2023: $79.70 · 2024: $50.79 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $331.02 | 2019-2025 | Vivitrol |
| Indivior INC. | $67.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.78 | 2025 | |
| Abbvie INC. | $37.74 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $35.80 | 2024-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $24.99 | 2023 | Dificid, Delstrigo, Pifeltro |
| Lilly USA, LLC | $18.76 | 2025 | Zepbound |
| Novo Nordisk INC | $18.34 | 2024 | Ozempic, Rybelsus |
| Pfizer INC. | $16.14 | 2023 | |
| Smith+Nephew, INC. | $15.32 | 2023 | Regranex, Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Heard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.